Want to see TNDM full AI Analyst Report?
Tandem Diabetes Care (TNDM) Stock Statistics & Valuation Metrics
Total Valuation
Tandem Diabetes Care has a market cap or net worth of $1.33B. The enterprise value is $1.32B.
- Market Cap
- $1.33B
- Enterprise Value
- $1.32B
Share Statistics
Tandem Diabetes Care has 69,578,705 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 69,578,705
- Owned by Insiders
- 1.01%
- Owned by Institutions
- 51.22%
Financial Efficiency
Tandem Diabetes Care’s return on equity (ROE) is -1.32 and return on invested capital (ROIC) is -11.88%.
- Return on Equity (ROE)
- -1.32
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -11.88%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 405.89K
- Profits Per Employee
- -81.88K
- Employee Count
- 2,500
- Asset Turnover
- 1.15
- Inventory Turnover
- 3.76
Valuation Ratios
The current PE Ratio of Tandem Diabetes Care is -20.58. Tandem Diabetes Care’s PEG ratio is -0.19.
- PE Ratio
- -20.58
- PS Ratio
- 1.28
- PB Ratio
- 10.02
- Price to FCF
- -49.95
- Price to Operating Cash Flow
- -236.62
- PEG Ratio
- -0.19
Income Statement
In the last 12 months, Tandem Diabetes Care had revenue of 1.01B and earned -204.71M in profits. Earnings per share was -3.04.
- Revenue
- 1.01B
- Gross Profit
- 530.85M
- Operating Income
- -78.12M
- Pretax Income
- -200.27M
- Net Income
- -204.71M
- EBITDA
- -174.70M
- Earnings Per Share (EPS)
- -3.04
Cash Flow
In the last 12 months, operating cash flow was -5.52M and capital expenditures -21.09M, giving a free cash flow of -26.62M billion.
- Operating Cash Flow
- -5.52M
- Free Cash Flow
- -26.62M
- Free Cash Flow per Share
- -0.39
Dividends & Yields
Tandem Diabetes Care pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.00%
- Earnings Yield
- -4.84%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- 30.98%
- 50-Day Moving Average
- 17.97
- 200-Day Moving Average
- 18.88
- Relative Strength Index (RSI)
- 62.36
- Average Volume (3m)
- 2.14M
Important Dates
Tandem Diabetes Care upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Tandem Diabetes Care as a current ratio of 2.55, with Debt / Equity ratio of 286.44%
- Current Ratio
- 2.55
- Quick Ratio
- 2.02
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- -2.03
- Interest Coverage Ratio
- -9.88
Taxes
In the past 12 months, Tandem Diabetes Care has paid 4.44M in taxes.
- Income Tax
- 4.44M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Tandem Diabetes Care EV to EBITDA ratio is -57.62, with an EV/FCF ratio of -75.37.
- EV to Sales
- 1.93
- EV to EBITDA
- -57.62
- EV to Free Cash Flow
- -75.37
- EV to Operating Cash Flow
- -363.16
Balance Sheet
Tandem Diabetes Care has $456.00M in cash and marketable securities with $739.25M in debt, giving a net cash position of -$283.26M billion.
- Cash & Marketable Securities
- $456.00M
- Total Debt
- $739.25M
- Net Cash
- -$283.26M
- Net Cash Per Share
- -$4.07
- Tangible Book Value Per Share
- $1.91
Margins
Gross margin is 56.01%, with operating margin of -4.13%, and net profit margin of -6.08%.
- Gross Margin
- 56.01%
- Operating Margin
- -4.13%
- Pretax Margin
- -5.86%
- Net Profit Margin
- -6.08%
- EBITDA Margin
- -3.34%
- EBIT Margin
- -5.07%
Analyst Forecast
The average price target for Tandem Diabetes Care is $26.77, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $26.77
- Price Target Upside
- 40.08% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 14
- Revenue Growth Forecast
- 3.92%
- EPS Growth Forecast
- 70.03%
Scores
- Smart Score
- 7
- AI Score
- 48
